Báo cáo khoa học: Adenine nucleotides inhibit proliferation of the human lung adenocarcinoma cell line LXF-289 by activation of nuclear factor jB1 and mitogen-activated protein kinase pathways doc

12 403 0
Báo cáo khoa học: Adenine nucleotides inhibit proliferation of the human lung adenocarcinoma cell line LXF-289 by activation of nuclear factor jB1 and mitogen-activated protein kinase pathways doc

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

Thông tin tài liệu

Adenine nucleotides inhibit proliferation of the human lung adenocarcinoma cell line LXF-289 by activation of nuclear factor jB1 and mitogen-activated protein kinase pathways Rainer Schafer1, Roland Hartig2, Fariba Sedehizade1, Tobias Welte3 and Georg Reiser1 ă Institut fur Neurobiochemie, Otto-von-Guericke-Universitat, Medizinische Fakultat, Magdeburg, Germany ă ă ă Institut fur Immunologie, Otto-von-Guericke-Universitat, Medizinische Fakultat, Magdeburg, Germany ă ă ă Klinik fur Pneumologie, Medizinische Hochschule Hannover, Germany ă Keywords cell cycle progression; mitogen-activated protein kinase; nuclear factor-jB1; P2Y receptors; phosphatidylinositol-3-kinase; protein kinase C Correspondence G Reiser, Otto-von-Guericke-Universita ăt Magdeburg, Medizinische Fakultat, Institut ă fur Neurobiochemie, Leipziger Str 44; ă 39120 Magdeburg, Germany Fax: +49 391 6713097 Tel: +49 391 6713088 E-mail: georg.reiser@medizin uni-magdeburg.de (Received February 2006, revised 12 June 2006, accepted 16 June 2006) doi:10.1111/j.1742-4658.2006.05384.x Extracellular nucleotides have a profound role in the regulation of the proliferation of diseased tissue We studied how extracellular nucleotides regulate the proliferation of LXF-289 cells, the adenocarcinoma-derived cell line from human lung bronchial tumor ATP and ADP strongly inhibited LXF-289 cell proliferation The nucleotide potency profile was ATP ¼ ADP ¼ ATPcS > > UTP, UDP, whereas a,b-methylene-ATP, b,c-methylene-ATP, 2¢,3¢-O-(4-benzoylbenzoyl)-ATP, AMP and UMP were inactive The nucleotide potency profile and the total blockade of the ATP-mediated inhibitory effect by the phospholipase C inhibitor U-73122 clearly show that P2Y receptors, but not P2X receptors, control LXF-289 cell proliferation Treatment of proliferating LXF-289 cells with 100 lm ATP or ADP induced significant reduction of cell number and massive accumulation of cells in the S phase Arrest in S phase is also indicated by the enhancement of the antiproliferative effect of ATP by coapplication of the cytostatic drugs cisplatin, paclitaxel and etoposide Inhibition of LXF-289 cell proliferation by ATP was completely reversed by inhibitors of extracellular signal related kinase-activating kinase ⁄ extracellular signal related kinase ⁄ (PD98059, U0126), p38 mitogen-activated protein kinase (SB203508), phosphatidylinositol-3-kinase (wortmannin), and nuclear factor jB1 (SN50) Western blot analysis revealed transient activation of p38 mitogen-activated protein kinase, extracellular signal-related kinase ⁄ 2, and nuclear factor jB1 and possibly new formation of p50 from its precursor p105 ATPinduced attenuation of LXF-289 cell proliferation was accompanied by transient translocation of p50 nuclear factor jB1 and extracellular signalrelated kinase ⁄ to the nucleus in a similar time period In summary, inhibition of LXF-289 cell proliferation is mediated via P2Y receptors by activation of multiple mitogen-activated protein kinase pathways and nuclear factor jB1, arresting the cells in the S phase Abbreviations a,b-MeATP, a,b-methylene adenosine 5¢-triphosphate; b,c-MeATP, b,c-methylene adenosine 5¢-triphosphate; BrdU, bromodeoxyuridine; Bz-ATP, 2¢,3¢-O-(4-benzoylbenzoyl)adenosine 5¢-triphosphate; CaMKII, calcium ⁄ calmodulin-dependent protein kinase; ERK, extracellular signalregulated kinase; GPCR, G protein-coupled receptor; MAPK, mitogen-activated protein kinase; MEK1 ⁄ 2, ERK-activating kinase; 2MeS-ADP, 2-methylthioadenosine 5¢-diphosphate; 2MeS-ATP, 2-methylthioadenosine 5¢-triphosphate; NF-jB, nuclear factor jB; NSCLC, nonsmall cell lung cancer; PI3K, phosphatidylinositol-3-kinase; PKC, protein kinase C; PLC, phospholipase C 3756 FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ê 2006 FEBS R Schafer et al ă plastic action of extracellular nucleotides on the human lung adenocarcinoma cell line LXF-289, which is derived from solid lung adenocarcinoma Extracellular nucleotides strongly attenuated the cell cycle progression of proliferating LXF-289 cells, leading to marked arrest of the cells in the S phase This inhibition is mediated by P2Y receptors through signaling pathways involving activation of the transcription factor nuclear factor jB1 (NF-jB1) and the MAPKs extracellular signal-related kinase ⁄ (ERK1 ⁄ 2) and p38 Our findings underline the importance of extracellular nucleotides in the specific modulation of cell proliferation Results Extracellular nucleotides attenuate LXF-289 cell proliferation via P2Y receptors Single pulses of ATP and ADP equipotently inhibited LXF-289 cell proliferation The effect was concentration-dependent, with half-maximal inhibition at 18.6 ± 1.9 lm (n ¼ 5) and 19.8 ± 0.6 lm (n ¼ 5), respectively (Fig 1) Significant inhibition was already 100 BrdU incorporation (% of control) There is growing evidence that extracellular nucleotides can regulate the proliferation of numerous tumorigenic or nontumorigenic tissues The nucleotide-activated purinergic P2 receptor family comprises the ionotropic P2X receptor ion channels and the metabotropic, G protein-coupled P2Y receptors [1–3] Seven subtypes of the P2X receptors (P2X1)7) and eight subtypes of the P2Y receptors (P2Y1,2,4,6,11,12,13,14) have been identified and functionally characterized [4,5] The regulatory function of extracellular nucleotides on cell growth, the role of nucleotides as effectors of neoplastic transformation and the ubiquitous expression of the purinergic receptors led to the investigation of the therapeutic potential of nucleotides and P2 receptors in clinical trials targeting various diseases (for review see [6]) ATP is already known to inhibit the growth of various tumors by activating specific P2 receptors Inhibition of cancer growth by adenine nucleotides was first described by Rapaport [7] In vitro extracellular nucleotides exert a strong antineoplastic effect on breast, ovarian [8], skin [9], prostate [10], endometrium [11], esophagus [12], intestinal [13] and colorectal carcinoma [14], suggesting that extracellular nucleotides can suppress tumorigenesis In view of the antineoplastic action of extracellular nucleotides [6] and the significant in vivo antitumor activity of intraperitoneally injected ATP against several aggressive carcinomas in tumor-bearing mice [7,15], it will be important to understand how the different P2 receptor subtypes contribute to the regulation of cancer cell proliferation In the majority of cell lines, P2Y receptors mediate the inhibition of growth or proliferation, whereas only a few cases have been reported where control of proliferation had been claimed to be mediated by P2X receptors Activation of P2X5 receptors stimulated the differentiation of skin cancer cells with subsequent inhibition of proliferation [16], and induction of cell death was mediated via P2X7 receptors in skin cancer and prostate cancer cells [16,17] The formation of the lytic pore of the P2X7 receptor is dependent on coordinated signaling involving the p38 mitogen-activated protein kinase (MAPK) pathway and caspase activation [18] Several mechanisms have been found for the inhibitory action of ATP on cancer cell growth In tumor cell lines from colon [14], endometrium [11], and esophagus [12], activation of P2Y receptors caused inhibition of proliferation by induction of cell cycle arrest and ⁄ or apoptosis However, the pathways involved in P2Y receptor-mediated attenuation of cell proliferation are not known Therefore, we here explored which pathways are involved in the antineo- ATP and ADP inhibit lung cell proliferation 80 60 40 Control ATP ADP UTP UDP 2-MeSADP Ado 20 10 20 40 60 100 nucleotide concentration [µM] Fig Concentration-dependent inhibition of LXF-289 cell proliferation by different nuccleotides Increasing concentrations (10–100 lM) of the different nucleotides were added to proliferating LXF-289 cells, and bromodeoxyuridine (BrdU) incorporation was measured after 12 h Values are means ± SD of n ¼ 4–7 experiments run in triplicate FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS 3757 ATP and ADP inhibit lung cell proliferation R Schafer et al ă Table Inhibition of proliferation of LXF-289 lung tumor cells Effects of P2 receptor agonists The influence of the different P2 receptor agonists is shown as percentage inhibition of the proliferation of LXF-289 cells Bromodeoxyuridine (BrdU) incorporation into proliferating LXF-289 cells LXF-289 cells in 96-well plates were incubated for h with 100 lM of the different nucleotides or nucleotide analogs listed below before the addition of 10 lM BrdU BrdU incorporation was determined by chemiluminescence as described in Experimental procedures, following incubation for 12 h Proliferation in the absence of nucleotides is taken as the reference value Inhibition of that value in percentage is given as means ± SD of 3–6 independent experiments run in triplicate Bz-ATP, 2¢,3¢-O-(4benzoylbenzoyl)adenosine 5¢-triphosphate; 2MeS-ADP, 2-methylthioadenosine 5¢-diphosphate; 2MeS-ATP, 2-methylthioadenosine 5¢-triphosphate P2 receptor agonist Inhibition of proliferation (%) ATP ADP ATPcS Bz-ATP UTP UDP a,b-MeATP b,c-MeATP 2-MeSADP 2-MeSATP UMP AMP 55.0 54.7 59.5 10.8 22.5 25.6 5.6 6.8 5.0 5.9 7.3 11.7 ± ± ± ± ± ± ± ± ± ± ± ± 5.1 4.6 3.8 5.1 3.6 2.3 4.1 5.7 1.6 1.1 2.3 5.9 a,b-methylene-ATP (a,b-MeATP) and b,c-MeATP, which preferentially activate P2X receptors, and AMP or UMP displayed no activity (Table 1) Moreover, adenosine, which is known to tightly regulate the proliferation of tumor cells [19], had no effect on the proliferation of LXF-289 cells up to concentrations of 100 lm (Fig 1) Likewise, 2-methylthio-ADP (2-MeSADP), 2-methylthio-ATP (2-MeSATP) and 2¢,3¢-O-(4benzoylbenzoyl)-ATP (Bz-ATP), which most potently activate human P2Y1,12 and P2Y11 receptors, respectively [20,21], did not influence the proliferation of LXF-289 cells (Table 1) Thus, the pharmacologic profile of the different nucleotides or nucleotide analogs tested strongly indicates that P2Y, but not P2X, receptors attenuate LXF-289 cell proliferation We next examined the expression of P2Y (P2Y1,2,4,6,11,12,13) and P2X (P2X3,4,7) receptors in LXF-289 cells by RT-PCR using primers specific for the human isoforms There was evidence for the expression of mRNA for the P2Y receptor subtypes P2Y2, P2Y6, P2Y11 and P2Y13 and for the P2X4 receptor, whereas expression of the P2Y1, P2Y4, P2Y12, P2X3 and P2X7 receptors could not be detected (Fig 2) Inhibition of growth and cell cycle progression of LXF-289 cells seen at 10 lm ATP (18.2 ± 4.9%; P < 0.01) or ADP (18.5 ± 3.5%; P < 0.01), which exhibited a reduction of 55% at 100 lm concentration The pyrimidine nucleotides UTP and UDP reduced the proliferation at 100 lm only by 23–26% (Table 1) ATPcS inhibited the proliferation of LXF-289 cells as potently as ADP and ATP (Table 1) Other nucleotides, such as P2Y1 P2Y2 P2Y4 P2Y11 P2Y6 We confirmed that the attenuation of DNA synthesis by ATP or ADP was indeed due to growth inhibition of LXF-289 cells Treatment of proliferating LXF-289 cells with 100 lm ATP or ADP reduced the cell number We observed reductions by 19.1 ± 3.8% (± SD; n ¼ 3) and 20.8 ± 4.4% (± SD; n ¼ 3) after 24 h, and by 54.0 ± 4.3% (± SD; n ¼ 3) and 54.1 ± 2.6% P2Y13 P2Y12 812 P2X4 P2X3 GAPDH P2X7 855 630 442 420 Fig Expression of P2 receptors in LXF-289 cells RT-PCR analysis was performed using primers for P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 receptors and the P2X receptors P2X3, P2X4 and P2X7 in LXF-289 cells PCR products were separated in a 1% agarose gel and visualized with ethidium bromide GAPDH, glyceraldehyde-3-phosphate dehydrogenase Sizes of RT-PCR products of the different P2 receptors are indicated 3758 FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS R Schafer et al ă A S-phase cells (% of total) (± SD; n ¼ 3) after 48 h, respectively These results confirm the identical potency of ATP and ADP in the inhibition of LXF-289 cell proliferation Cell cycle analysis revealed that inhibition of proliferation of LXF-289 cells by ATP and ADP was mediated by retardation of cell cycle progression Flow cytometry analysis of subconfluent LXF-289 cell cultures showed that treatment with ATP or ADP (10– 100 lm) for 24 h caused a concentration-dependent increase of cells in the S phase With 100 lm ATP and ADP, 74.6 ± 3.2% (n ¼ 3) and 66.4 ± 1.3% (n ¼ 3) of the cells, respectively, were arrested in S phase (Fig 3A) Figure 3B illustrates the changes of the cell cycle distribution induced by two concentrations of ATP in LXF-289 cells ATP and ADP inhibit lung cell proliferation control 80 ADP ATP 60 40 20 10 µM B 20 µM a b 50 µM 100 µM c control 16 ATP sensitizes LXF-289 cells to the activity of anticancer drugs Signal transduction pathways involved in nucleotide-mediated inhibition of proliferation of LXF-289 cells Different mechanisms and signal transduction pathways transduce control of proliferation by G protein- 80 c e l l s (c o u n t s / c h a n n e l ) Extracellular nucleotides caused accumulation of LXF289 cells in the S phase, where cells are especially sensitive to anticancer drugs Therefore, we used cisplatin, etoposide and paclitaxel to investigate the effects of these anticancer drugs on LXF-289 cells in the presence of ATP These anticancer substances inhibit cell cycle progression by different mechanisms and form the basis of current chemotherapeutic regimens in lung cancer treatment Cisplatin, etoposide and paclitaxel dosedependently inhibited the proliferation of LXF-289 cells with IC50 values of 13.8 ± 1.3 lm (n ¼ 3), 19.4 ± 2.2 lm (n ¼ 3), and 16.2 ± 1.4 nm (n ¼ 3), respectively (Fig 4) The simultaneous addition of 100 lm ATP enhanced the antiproliferative potency of cisplatin 3-fold, of etoposide 2-fold and of paclitaxel 2.5-fold, with resulting IC50 values of 4.7 ± 0.8 lm, 9.3 ± 2.3 lm and 6.8 ± 1.2 nm (Fig 4) The data suggest an additive effect of the anticancer drugs and ATP on proliferation, and support our conclusion that in LXF-289 cells the ATP-mediated arrest of cell cycle progression targets the S phase We did not find any significant induction of DNA fragmentation in LXF-289 cells or an increase in the number of dead cells under our assay conditions (data not shown) Moreover, the concentrations of cisplatin and etoposide used not induce significant apoptosis in other human lung cancer cells such as A549 cells, as reported by others [22,23] G0-G1: 65.74% S-Phase: 26.27% 20 µM ATP 16 G0-G1: 40.40% S-Phase: 48.39% 80 100 µM ATP 16 G0-G1: 19.91% S-Phase: 77.97% 80 0 20 40 60 80 Fig Effect of ATP and ADP on cell cycle progression of LXF-289 cells (A) Accumulation of LXF-289 cells in the S phase LXF-289 cells were incubated with ATP or ADP (10–100 lM) for 24 h, and the distribution of cells in the different cell cycle phases was analyzed by fluorescence-activated cell sorting (FACS) (B) Differences in the cell cycle distribution of LXF-289 cells Depicted are the percentages of the cells in the G0 ⁄ G1, S and G2 ⁄ M phases of the cell cycle after treatment with 20 lM or 100 lM ATP for 24 h The gating used for the quantification of the cells in the G0 ⁄ G1 (a), S (b) and G2-M (c) phases is depicted by the respective bar coupled receptors (GPCRs) We therefore investigated which of the pathways found in GPCR-mediated attenuation of cell proliferation, including phospholipase C (PLC), protein kinase C (PKC) and extracellular Ca2+ influx, are involved in the control of LXF-289 cell proliferation by P2Y receptors At a concentration of 10 lm, the PLC inhibitor U-73122 completely reversed the effect of ATP on FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS 3759 ATP and ADP inhibit lung cell proliferation A 120 R Schafer et al ¨ + Cisplatin + ATP-Cisplatin B r d U i n c o r p o r a t i on ( % o f b a s a l ) + Etoposide 100 + ATP-Etoposide Control + ATP 80 60 40 20 Table Inhibition of proliferation of LXF-289 lung tumor cells Effects of signaling pathway inhibitors on ATP-inhibited proliferation (A) and of basal proliferation (B) of LXF-289 lung tumor cells Proliferating LXF-289 cells in 96-well plates were incubated for h with the various signal transduction pathway inhibitors listed below before the addition of 100 lM ATP (ATP) or medium (B) Bromodeoxyuridine (BrdU) incorporation was then determined by chemiluminescence as described in Experimental procedures following incubation for 12 h (A) Data give percentage reduction of the inhibitory effect exerted by ATP on BrdU incorporation The inhibition of proliferation of LXF-289 cells by 100 lM ATP (see value in Table 1) is taken as 100% (B) Basal incorporation of BrdU into proliferating LXF-289 cells in the presence of the inhibitors for the kinases calcium ⁄ calmodulin-dependent protein kinase (CaMKII), extracellular signal-regulated kinase ⁄ (ERK1 ⁄ 2), p38 mitogen-activated protein kinase (MAPK), protein kinase C and PI3 kinase All values are means ± SD of 3–6 independent experiments run in triplicate (A) B 10 cisplatin, etoposide (µM) 120 100 Signaling pathway inhibitors + Paclitaxel B r d U i nc o r po r a t i o n ( % o f b a s a l ) + ATP-Paclitaxel Control + ATP 100 80 60 40 20 Reduction of inhibitory effect of ATP (%) U-73122 U-73343 SKF-96365 KN-62 Wortmannin PD98059 U0126 SB203580 Go6983 ¨ Go6983 ¨ NF-jB SN50 Curcumin Sulindac sulfide 10 lM 10 lM 50 lM 25 lM 0.1 lM 20 lM lM 20 lM 0.1 lM 1.0 lM 20 lM 20 lM 10 lM 101 8.1 79.8 98.6 93.9 92.8 91.8 95.1 24.6 86.7 94.2 97.1 88.4 ± ± ± ± ± ± ± ± ± ± ± ± ± 6.4 7.0 4.7 3.7 3.2 3.3 4.1 2.9 4.1 2.8 5.3 1.9 9.0 (B) Kinase inhibitors 0 10 paclitaxel (nM) 100 Fig Effect of anticancer drugs and ATP on proliferation of LXF289 cells Bromodeoxyuridine (BrdU) incorporation into DNA was measured in LXF-289 cells (control) or cells incubated with different concentrations of the anticancer drugs cisplatin or etoposide (A) or paclitaxel (B) in the absence (solid symbols) or presence (open symbols) of 100 lM ATP Values (means ± SD of four or five independent experiments run in triplicate) are expressed as percentage of BrdU incorporation into DNA in cells without the addition of either ATP or the anticancer drugs (basal proliferation ¼ 100% control) IC50 values were calculated using the SIGMAPLOT curve-fitting program (SPSS, Chicago, IL, USA) LXF-289 cell proliferation, whereas the inactive analog U-73343 had no effect (Table 2) Blockade of receptoroperated Ca2+ channels with SKF-96365 dose-dependently reduced the inhibitory effect of ATP (data not 3760 Concentration Concentration Reduction of basal proliferation (%) KN-62 Wortmannin PD98059 U0126 SB203580 Go6983 ă Go6983 ă 25 lM 0.1 lM 20 lM lM 20 lM 0.1 lM 1.0 lM 5.6 8.7 8.8 7.9 5.8 4.8 6.5 ± ± ± ± ± ± ± 2.4 4.8 5.7 5.1 4.2 2.3 2.8 shown) A reduction of 80% was seen at 50 lm (Table 2) This result and the pharmacologic profile obtained for inhibition of proliferation clearly show that P2Y receptors mediate the attenuation of LXF289 cell proliferation Preincubation of LXF-289 cells with the potent PKC inhibitor Go-6983 concentration-dependently ă abolished the antiproliferative effect of ATP (Table 2) In addition, we investigated the involvement of the FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS R Schafer et al ă calcium calmodulin-dependent kinase II (CaMKII), which is also known to regulate cell cycle progression and proliferation Inhibition of CaMKII activity by KN-62 (25 lm) completely reduced the inhibition by ATP The inhibition of LXF-289 cell proliferation by 100 lm ATP was totally attenuated by blockers of either ERK-activating kinase (MEK1 ⁄ 2) (20 lm PD98059, lm U0126), p38 MAPK (20 lm SB203580) or phosphatidylinositol-3-kinase (PI3K) (wortmannin), indicating that each pathway seems to be involved in ATP-mediated inhibition of LXF-289 cell proliferation (Table 2) Inhibition of the MAPK cascade enzymes MEK1 ⁄ and p38 MAPK by their selective inhibitors PD98059 ⁄ U0126 and SB203580, respectively, antagonized the nucleotide-mediated inhibition of cell proliferation in a concentration-dependent manner (data not shown) We further investigated whether the activation of ERK1 ⁄ and p38 MAPK may be part of the antiproliferative activity of ATP, as these kinases are important regulators of proliferation as well as apoptosis Western blotting revealed a time-dependent increase in both ERK1 and ERK2 phosphorylation with 100 lm ATP (Fig 5A) ERK1 ⁄ activation was maximal in the cytosolic fraction after 10 and had strongly declined below the control level after 20 Concomitant with this rapid activation, a transient translocation of activated ERK1 ⁄ into the nuclear fraction was induced by ATP The translocation was maximal at 10 and declined thereafter, with no active ERK1 ⁄ detectable in the nuclear fraction after 60 (Fig 5A) Exposure of LXF-289 cells to ATP also caused rapid phosphorylation of p38 MAPK (Fig 5B) Again, as for ERK1 ⁄ 2, maximal activation was seen at 10 after addition of ATP However, in contrast to ERK1 ⁄ 2, no translocation of activated p38 MAPK to the nucleus could be detected Instead, after a rapid decline of phosphorylated p38 MAPK down to undetectable levels after 30 min, activated p38 MAPK reappeared at 60 after addition of agonist (Fig 5B) These results further indicate the involvement of both MAPKs, ERK1 ⁄ and p38, in the signaling pathways, consistent with the inhibition of the antiproliferative activity of ATP by the MEK1 ⁄ inhibitors PD98059 and UO126 and the p38 MAPK inhibitor SB20358 (Table 1) The differences in the phosphorylation of ERK1 ⁄ and p38 MAPK are not due to altered expression of ERK1 ⁄ and p38 MAPK, as western blotting of total cell lysates did not reveal any change of either kinase after treatment with 100 lm ATP for up to 60 (Fig 5C) ATP and ADP inhibit lung cell proliferation Cytosol Nucleus 10 20 30 60 kDa 10 20 30 60 [min] 50 A phospho-ERK 1/2 37 50 B phospho-p38 37 Cell lysate kD 10 30 60 C [min] ERK 1/2 37 p38 37 Cytosol kD D 10 50 E 75 Nucleus 10 20 30 60 10 20 30 [min] p105 NF-κB1 p50 RelA (p65) 50 Fig ATP-mediated activation and nuclear translocation of extracellular signal-related kinase ⁄ (ERK1 ⁄ 2), p38 mitogen-activated protein kinase (MAPK) and nuclear factor jB (NF-jB) LXF-289 cells were incubated with 100 lM ATP, and the incubation was stopped by aspiration of the medium at the different time points indicated After preparation of subcellular fractions as described in Experimental procedures, proteins were separated by SDS ⁄ PAGE and transferred to nitrocellulose Blots from cytosolic and nuclear fractions were incubated with antibodies to (A) phospho-ERK1 ⁄ (1 : 1000 dilution) and (B) phospho-p38 MAPK (1 : 1000 dilution), and with polyclonal antibodies (1 : 1000 dilution) specific for (D) NF-jB1 (p50 and p105) and (E) RelA (p65) Total cell lysate (C) was incubated with antibodies to total ERK1 ⁄ and p38, respectively Primary antibodies were incubated at °C overnight, and horseradish peroxidase (HRP)-conjugated secondary antibody (1 : 20 000 dilution) was incubated for 1.5 h at room temperature The antibody reaction was visualized with enhanced chemiluminescence The positions of the protein molecular mass markers are indicated in kilodaltons (kDa) The experimental data shown are typical for three independent experiments performed with different passages of LXF-289 cells Activation of the transcription factor NF-jB can lead to induced tumor proliferation or to suppression of tumor growth, resulting in apoptosis [24] Therefore, we also investigated the involvement of NF-jB in nucleotide-mediated inhibition of LXF-289 cell proliferation Preincubation of LXF-289 cells with the NF-jB1 inhibitory peptide NF-jB SN50 (20 lm) completely abrogated the inhibitory effect of 100 lm ATP (Table 2) This suggests that inhibition of LXF-289 cell proliferation by ATP is mediated through NF-jB Further evidence for the involvement of NF-jB in the signaling pathway activated by P2Y receptors was obtained by the use of nonsteroidal anti-inflammatory drugs, which have been shown to inhibit activation of FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS 3761 ATP and ADP inhibit lung cell proliferation R Schafer et al ă NF-jB and cancer cell proliferation [25–27] Curcumin (20 lm) and sulindac sulfide (10 lm) totally abolished the ATP-induced inhibition of LXF-289 cell proliferation (Table 2), without inhibiting LXF-289 cell proliferation at this concentration in the absence of nucleotides (data not shown) These results further support the involvement of NF-jB in the P2Y receptor-mediated control of LXF-289 cell proliferation Western blot analysis showed that incubation of LXF-289 cells with 100 lm ATP caused a detectable decrease of the p50 form of NF-jB1 in the cytosol after 10 min, which is still visible after 60 (Fig 5D) Simultaneously with the decrease of p50 in the cytosol, an increase of NF-jB1 p50 in the nuclear fraction could be observed, starting after 10 min, which persisted after 60 of nucleotide exposure (Fig 5D) Signaling by ATP also influenced the formation of p50 from its precursor p105 Partial degradation of the p105 form of NF-jB1, which has an inhibitory function in the cytosol, like the inhibitor jB (IjB)s, to the p50 form is visible after 20–30 (Fig 5D) Thus, ATP not only induced the translocation of NF-jB1, but also possibly led to newly formed p50 from the precursor p105 In addition, ATP induced the disappearance of p65 NF-jB from the cytosol after 20–30 min, but, surprisingly, no translocation into the nucleus was observed (Fig 5E) These data suggest that NF-jB1 and p65 have different roles in the cell cycle regulation of proliferating LXF-289 cells by nucleotides Discussion Our data demonstrate an important role of extracellular nucleotides in the regulation of proliferation of human lung tumor cells Thus far, it has not been found that extracellular nucleotide P2Y receptors downregulate cell cycle progression in epithelial cells via activation of NF-jB Attenuation of LXF-289 cell proliferation by ATP is mediated by the activation of the MEK ⁄ ERK1 ⁄ 2, PI3K and p38 MAPK pathways Activation and translocation of the transcription factors NF-jB1 (p50) and RelA (p65) was also involved These pathways lead to a massive arrest of the cells in the S phase Activation of NF-jB by P2Y receptors has only been found so far to be associated with the stimulation of cell proliferation, such as in osteoclasts [28] or A549 alveolar lung tumor cells [29] The activity profile of the different nucleotides and nucleotide analogs used, as well as the complete inhibition of the antiproliferative effect of ATP by the PLC inhibitor U-73122, clearly indicate that P2Y receptors, but not P2X receptors, mediate the inhibition of LXF-289 lung cell proliferation The inability of 3762 2-MeSATP and Bz-ATP to influence the proliferation of LXF-289 cells excludes the participation of the P2Y11 receptor subtype in the inhibition Bz-ATP has been shown to activate human P2Y11 receptors, whereas 2-MeSATP activates the human P2Y11 receptor with similar potency as ATP [20] The pharmacologic profile seen here for the inhibition of proliferation best fits the characteristics of the subtypes P2Y2 and P2Y13, which were found to be expressed in LXF-289 cells by RT-PCR Thus, our data suggest that these P2Y receptors are involved in the downregulation of LXF-289 cell proliferation The P2Y2 receptor has been found to be important for the proliferation of stem cells and of human melanomas, and to play a role during differentiation as well as during development and aging [9,30–32] However, our finding here that ATP was much more potent than UTP is not consistent with the equipotent activation of the P2Y2 receptor by ATP and UTP (reviewed in [3]) Similarly, the inactivity of 2-MeSADP, which is more potent than ADP at the human P2Y13 receptor [33], creates another conundrum Similaryl, a nucleotide activity profile, which was not consistent with the pattern of P2Y receptors expressed, posed an enigma in the work by Neary and coworkers, where the stimulation of the ERK cascade in rat cortical astrocytes by nucleotide analogs was studied [34] The control of LXF-289 cell proliferation by purinergic metabotropic P2Y receptors involves the activation of multiple pathways One pathway activates the transcription factor NF-jB, a major regulatory factor of proliferation and apoptosis Attenuation of LXF289 cell proliferation by extracellular ATP is mediated by the induction of nuclear translocation of p50 NF-jB1 and possibly new formation of p50 from its precursor p105 This unique activation of NF-jB during attenuation of cell proliferation through P2Y receptors has been found for the first time Thus far, activation of NF-jB through P2Y or P2X receptors has been associated with stimulation of proliferation of different cell types This has been reported for lung alveolar tumor cells [29], osteoclasts [28], T cells [35] and human monocytes [36] We also found a decrease of p65 in the cytosolic fraction, but no corresponding accumulation in the nuclear fraction, suggesting a different role and site of action for the NF-jB forms p50 and p65 in nucleotide-mediated growth control Genetic deletion studies have revealed an important role for NF-jB1 in the regulation of the proliferation and fate of neural progenitor cells [37] Moreover, NF-jB1 p50 plays a central role in the pathogenesis of classical Hodgkin’s lymphoma and in anaplastic large-cell lymphomas, complexed with BCL-3 [38] FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ê 2006 FEBS R Schafer et al ă In addition to the transcription factor NF-jB1, extracellular ATP simultaneously activates the MAPK signaling pathways of p38 MAPK and ERK1 ⁄ The simultaneous activation of both MAPK pathways is indicated by the similar time dependence in the activation of ERK1 ⁄ and p38 MAPK Both pathways seem to be involved in the downregulation of the proliferation of LXF-289 cells This is indicated by the fact that blockage of either pathway by the inhibitors for p38 MAPK and ERK1 ⁄ completely reversed the inhibitory effect of ATP on LXF-289 cell proliferation Inhibitor blockage of either pathway completely reversed the inhibition of LXF-289 cell proliferation by ATP Further indirect support for the involvement of ERK1 ⁄ is derived from the observed translocation of ERK1 ⁄ to the nucleus The translocation of activated ERK1 ⁄ to the nucleus is a prerequisite for the control of cell cycle progression [39,40] The significance of ERK and p38 phosphorylation for the activation of specific gene products under these conditions of downregulation of cell cycle progression via P2Y receptors still has to be identified There are multiple targets (e.g transcription factors E2F, ETS, ATF and AP1, p27(KIP); HBP1, pRB) that can be phosphorylated by ERK1 ⁄ and ⁄ or p38 MAPK and are possibly involved in the promotion of cell cycle progression and the regulation of the cell cycle checkpoints (for reviews see [41–45]) Recent advances indicate a number of links between the activation of p38 kinase and the DNA checkpoint pathways and their possible interaction in the modulation of cell cycle control and DNA mismatch repair [46–50] Intriguingly, another mechanism by which p38 MAPK may negatively regulate the cell cycle is by activation of the mitotic spindle assembly checkpoint pathway that monitors the correct formation of the spindle and attachment of kinetochores [51,52] There is extensive crosstalk between the ERK1 ⁄ 2activated, p38 MAPK-activated and NF-jB-activated pathways The simultaneous activation of ERK1 ⁄ 2, p38 kinase and NF-jB1 has been described only for inflammatory mediators, such as lipopolysaccharide or tumor necrosis factor-a (reviewed in [53]), but not for extracellular nucleotides Thus, in addition to the control of lymphocyte or macrophage function, the simultaneous activation of these pathways may participate in the attenuation of epithelial cell proliferation by extracellular nucleotides Moreover, in some systems GPCRs couple to NF-jB through sequential activation of conventional PKC isoforms and IjB kinase, leading to degradation of IjB by the proteasome [54] It is possible that the P2Y receptors act through PKC or, alternatively, through PI3K to activate NF-jB in lung ATP and ADP inhibit lung cell proliferation tumor cells However, we not know whether these pathways converge at a single target, e.g NF-jB, or whether they interfere with the regulation of S phase entry, S phase progression and ⁄ or exit from S phase to G2 phase Until now, P2Y receptor-mediated inhibition of cell proliferation by control of cell cycle progression has been found only in esophageal cells [12] Activation of P2Y receptors by ATP and ADP inhibits LXF-289 cell proliferation very likely through direct attenuation of S phase progression This is indicated by the massive increase of cells in the S phase, the reduction in cell proliferation, and the decrease in bromodeoxyuridine (BrdU) incorporation into newly synthesized DNA In addition, the additive effect of ATP with that of paclitaxel and etoposide also suggests that ATP inhibits growth by interfering with cell cycle progression at the S phase Paclitaxel and etoposide exert a block of NSCLC cells at the G2 ⁄ M and G2 phase, respectively [22,23], whereas cisplatin causes an accumulation of G0 ⁄ G1 cells [55] The transient translocation of ERK1 ⁄ and of p50 NF-jB1 to the nucleus suggests a role of both proteins in the regulation of cell cycle progression by extracellular nucleotides Sustained activation of the ERK1 ⁄ and PI3K pathways is not only necessary for cell cycle progression into S phase but also regulates progression during G2 ⁄ M phase by distinct cell cycle timing requirements [39,56] However, we observed only transient ERK1 ⁄ activity in the nucleus for up to 60 min, which is much shorter than the sustained activity for ERK1 ⁄ 2, which persists from late S phase to G2 and M phases [39] Moreover, nothing is known about a direct link of NF-jB1 with regulation of the S phase checkpoint or S phase progression Thus, for both proteins, the mechanistic details of inhibition of cell cycle progression remain unclear Different mechanisms can be targeted for attenuation of cell cycle progression Putative targets for nucleotideregulated cell cycle progression are either (a) the activation of cell cycle-regulated kinases, Cdc7, and cyclin dependent kinase, which are required for the initiation of DNA replication during S phase, or (b) the recruitment of the initiation factor Cdc45, which is required for the elongation phase of replication, or (c) the replication forks (reviewed in [57]) Especially in the last case, extracellular nucleotides may perhaps act as a signal causing replication forks to stall and halt cell cycle progression, similar to energy depletion or DNA damage (see review [57]) However, this needs to be investigated for extracellular nucleotides This is very important to understand, because the stabilization of stalled replication forks is crucial for maintaining cell viability [57] FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS 3763 ATP and ADP inhibit lung cell proliferation R Schafer et al ă In summary, our results reveal that extracellular nucleotides inhibit proliferation of LXF-289 cells by regulation of cell cycle progression through activation of several signal transduction pathways The delay in cell cyle progression through activation of P2Y receptors is possibly mediated by activation of the NF-jB1 isoform of transcription factor NF-jB, the MAPKs ERK1 ⁄ and p38 and PI3K Thus, extracellular nucleotides need to be added to the class of the critical regulators of cell cycle progression, so far consisting of hormones, growth factors, and cytokines Further detailed investigations are needed to unravel the subtype of P2Y receptor mediating the observed response and the functionality of the proteins in the signaling mechanisms that lead to the attenuation of cell cycle progression Experimental procedures Cell culture and reagents The human lung adenocarcinoma cell line LXF-289, established from the solid lung tumor of a 63-year-old man, was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) LXF289 cells were cultured in Ham’s F-10 (Biochrom, Berlin, Germany) supplemented with 10% FBS, 100 ImL)1 penicillin, and 100 lgỈmL)1 streptomycin in a 5% CO2 incubator at 37 °C Paclitaxel, etoposide and cisplatin were purchased from Calbiochem (Bad Soden, Germany) The PKC inhibitors Go6983 (Alexis, Grunberg, Germany), ă ă U-73122, U-73343, SB-203580, wortmannin (Sigma-Aldrich, Taufkirchen, Germany), KN-62, PD-908059 (Bio-Trend, Koln, Germany), SKF-96365 and NF-jB SN-50 (Calbioă chem) were dissolved in dimethyl sulfoxide or in NaCl ⁄ Pi to give stock concentrations of 10 or 100 mm Measurement of cell proliferation Cell proliferation was measured by luminometric immunoassay based on BrdU incorporation during DNA synthesis using a cell proliferation ELISA BrdU Kit (Roche, Mannheim, Germany) according to the manufacturer’s protocol The effect of extracellular nucleotides on BrdU incorporation was measured in LXF-289 cells, as described [29] Cells were seeded on 96-well plates (5 · 103 cells per well) and then incubated for 24 h Cells were then incubated with 100 lm (standard conditions) of the different nucleotides or nucleotide analogs for h in a final volume of 100 lL per well Antagonists were added to the cells h before the addition of the nucleotides Subsequently, 10 lL of BrdUlabeling solution was added to each well and the cells were incubated again for 12 h BrdU labeling was determined as previously described [29] 3764 Cell growth was determined in subconfluent LXF-289 cells seeded into 12-well plates (5 · 104 cells per well; 500 lL per well) At 24 h after seeding, cells were treated with 100 lm ATP or ADP for or days Antagonists were added to the cells h before the addition of the nucleotides Cells were washed twice with NaCl ⁄ Pi, and dispersed using trypsin-EDTA, and suspended cells were counted using a hemacytometer The percentage inhibition of cell proliferation by nucleotide treatment was calculated by comparison with control cells Trypan blue was used to determine cell viability We ascertained in all cases that the inhibitor concentrations used did not affect basal DNA synthesis Therefore, we tested the effect of the compounds U-73122, U-73343, SB-203580, KN-62, PD-908059, SKF-96365 and NF-jB SN-50 in a concentration range from 0.1 to 100 lm and the inhibitors Go6983, U0126 and wortmannin in a concentraă tion range from 0.01 to 10 lm Maximal concentrations, which did not influence basal DNA synthesis, were used in the proliferation tests with the nucleotides The concentration-dependent inhibition (1–100-fold of initial concentration) of the antiproliferative effect of ATP was tested for the inhibitors U-73122, PD98059, SB203580, SKF-96365 and Go6983 (data not shown) ă Cell cycle analysis LXF-289 cells (5 Ã 104 cells per well) were seeded in 12well plates, cultured for 24 h and exposed to the respective nucleotide for another 24 h or 48 h Trypsinized cells were pelleted at 300 g, washed once with 0.5 mL of icecold NaCl ⁄ Pi and fixed in 75% ethanol at ) 20 °C for 60 Cells were treated with RNaseA (200 lgỈmL)1) and propidium iodide (50 lgỈmL)1) in NaCl ⁄ Pi at 25 °C for 30 min, and this followed by flow cytometry (FACScan; Becton Dickinson, Franklin Lakes, NJ) Distribution of the cells in G1, S and G2 ⁄ M phases and apoptotic populations (sub-G1 phase) were analyzed by the modfit program (Verity Software House Inc., Topsham, ME, USA) Determination of P2 receptor expression Expression of mRNA for different P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13) and P2X (P2X3, P2X4, and P2X7) receptors in LXF-289 cells was determined by RTPCR Total RNA was isolated from LXF-289 cells, as previously described [29], with the RNeasy kit (Qiagen, Hilden, Germany) Possible genomic DNA contamination was excluded in experiments by omitting the reverse transcriptase in the PCR Sets of specific oligonucleotide primers were synthesized based on the published sequences for the different P2Y receptors (see below) Primer sequences for P2Y1, P2Y2, P2Y4 and P2Y6 receptors were as described FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS R Schafer et al ă [29] Amplication was performed with lL of cDNA, for 30 cycles The sequences for the primers were 5¢CGA GGT GCC AAG TCC TGC CCT-3¢ (forward, positions 7–27) and 5¢-CGC CGA GCA TCC ACG TTG AGC-3¢ (reverse, positions 798–818) with 812 bp for hP2Y11 (accession no AF030335), 5¢-CCA GTC TGT GCA CCA GAG ACT-3¢ (forward, positions 115–135) and 5¢-ATG CCA GACTAG ACC GAA CTC-3¢ (reverse, positions 615–635) with 520 bp for hP2Y12 (accession no AF313449), and 5¢-GGT GAC ACT GGA AGC AAT GAA-3¢ (forward, positions 67–78) and 5¢-GAT GAT CTT GAG GAA TCT GTC-3¢ (reverse, positions 437–457) with 391 bp for hP2Y13 (accession no NM176894) The primers for the P2X3,4,7 were 5¢-AGT CGG TGG TTG TGA AGA GCT-3¢ (forward, positions 41–61) and 5¢-AAG TTC TCA GCT TCC ATC ATG-3¢ (reverse, positions 492– 512) with 472 bp for hP2X3 (accession no AB016608), 5¢-GCC TTC CTG TTC GAG TAC GAC-3¢ (forward, positions 1951–71) and 5¢-CGC ACC TGC CTG TTG AGA CTC-3¢ (reverse, positions 2351–2371) with 421 bp for hP2X4 (accession no AF191093), and 5¢-GTC ACT CGG ATC CAG AGC ATG-3¢ (forward, positions 148–168) and 5¢-TTG TTC TTG ATG AGC ACA GTG-3¢ (reverse, positions 660–680) with 533 bp for hP2X7 (accession no NM002562) Preparation of cell extracts and western blot analysis LXF-289 cells, seeded in 55 mm dishes, were incubated with 100 lm ATP at 37 °C for various times Cells were lysed with hypotonic buffer (20 mm Tris ⁄ HCl, pH 8.1, mm Mg2+, 0.05 mm Ca2+) containing an inhibitory cocktail for proteases and phosphatases (Complete EDTA; Roche) and mm NaVO4 (hereafter named lysis buffer) by incubation on ice for 15 min, dispersed by sonication and then centrifuged at 1000 g for 10 For all centrifugations an Avanti 30 centrifuge from Beckman Coulter (Krefeld, Germany) was used The resulting pellet, containing nuclei and mitochondria, was resuspended in lysis buffer containing 400 mm sucrose, layered on a sucrose cushion of 1.2 m sucrose in lysis buffer and centrifuged for 15 at 5000 g to purify the nuclei Purified nuclei were resuspended in lysis buffer containing 0.1% (v ⁄ v) Nonidet P-40, mm dithiothreitol and 0.4 m NaCl, incubated on ice for 30 to extract the proteins, and then centrifuged at 12 000 g for 10 to remove nonsolubilized debris The resulting supernatant (nuclear fraction) was stored at ) 80 °C for further investigations The supernatant from the first centrifugation (1000 g) was then centrifuged at 50 000 g for 45 to prepare the cytosolic fraction (resultant supernatant) The protein content was determined using the BCA protein assay kit (Pierce, Rockford, IL, USA) Protein fractions were subjected to SDS gel electrophoresis on 10% acrylamide gels and transferred to PVDF ATP and ADP inhibit lung cell proliferation membranes To control the complete and even transfer of proteins to the blotting membranes, membranes were immersed in a Ponceau Red-containing solution and the stained protein bands were scanned densitometrically before processing with antibodies Blots were incubated at °C overnight with anti-human phospho-ERK1 ⁄ (Thr183, Tyr185), anti-phospho-p38 MAPK (Cell Signaling Technology, Beverley, MA, USA) or antibodies for NF-jB1 (p50, p105) or RelA (p65) After incubation with horseradish peroxidase-conjugated anti-rabbit IgG (Dianova, Hamburg, Germany) for 1.5 h at room temperature, the antibody reaction was visualized by enhanced chemiluminescence (Promega, Madison, WI, USA) Statistical analyses Experiments were conducted with cultures from different seedings The number of replica experiment is given in the figure legends Data were analyzed by Student’s t-tests for two groups or anova for multiple groups Acknowledgements We thank Annette Schulze for skillful technical assistance in the experiments The work was supported by Deutsche Krebshilfe (project 10-1754) and Land Sachsen-Anhalt References Abbracchio MP & Burnstock G (1998) Purinergic signalling: pathophysiological roles Jpn J Pharmacol 78, 113–145 Burnstock G & Williams M (2000) P2 purinergic receptors: modulation of cell function and therapeutic potential J Pharmacol Exp Ther 295, 862–869 von Kugelgen I & Wetter A (2000) Molecular pharmaă cology of P2Y-receptors Naunyn Schmiedebergs Arch Pharmacol 362, 310–323 Dubyak GR (2003) Knock-out mice reveal tissue-specific roles of P2Y receptor subtypes in different epithelia Mol Pharmacol 63, 773–776 Khakh BS (2001) Molecular physiology of P2X receptors and ATP signalling at synapses Nat Rev Neurosci 2, 165–174 Burnstock G (2002) Potential therapeutic targets in the rapidly expanding field of purinergic signalling Clin Med 2, 45–53 Rapaport E (1983) Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle J Cell Physiol 114, 279–283 Popper LD & Batra S (1993) Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells Cell Calcium 14, 209–218 FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS 3765 ATP and ADP inhibit lung cell proliferation R Schafer et al ă White N, Ryten M, Clayton E, Butler P & Burnstock G (2005) P2Y purinergic receptors regulate the growth of human melanomas Cancer Lett 224, 81–91 10 Calvert RC, Shabbir M, Thompson CS, Mikhailidis DP, Morgan RJ & Burnstock G (2004) Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells Anticancer Res 24, 2853– 2859 11 Katzur AC, Koshimizu T, Tomic M, Schultze-Mosgau A, Ortmann O & Stojilkovic SS (1999) Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines J Clin Endocrinol Metab 84, 4085– 4091 12 Maaser K, Hopfner M, Kap H, Sutter AP, Barthel B, ă von Lampe B, Zeitz M & Scherubl H (2002) Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y2-receptors Br J Cancer 86, 636–644 13 Coutinho-Silva R, Stahl L, Cheung KK, de Campos NE, de Oliveira Souza C, Ojcius DM & Burnstock G (2005) P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation Am J Physiol Gastrointest Liver Physiol 288, G1024– G1035 14 Hopfner M, Maaser K, Barthel B, von Lampe B, ¨ Hanski C, Riecken EO, Zeitz M & Scherubl H (2001) Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate Int J Colorectal Dis 16, 154–166 15 Rapaport E & Fontaine J (1989) Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice Biochem Pharmacol 38, 4261–4266 16 Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, McGrouther DA & Burnstock G (2003) Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells J Invest Dermatol 121, 315–327 17 Janssens R & Boeynaems JM (2001) Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells Br J Pharmacol 132, 536–546 18 Donnelly-Roberts DL, Namovic MT, Faltynek CR & Jarvis MF (2004) Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells J Pharmacol Exp Ther 308, 1053–1061 19 Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA & Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy Pharmacol Ther 100, 31–48 20 Communi D, Robaye B & Boeynaems JM (1999) Pharmacological characterization of the human P2Y11 receptor Br J Pharmacol 128, 1199–1206 3766 21 Vigne P, Hechler B, Gachet C, Breittmayer JP & Frelin C (1999) Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation Biochem Biophys Res Commun 256, 94–97 22 Dan S & Yamori T (2001) Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells Biochem Biophys Res Commun 280, 861–867 23 Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, Bruno S, Grossi F, Scolaro T & Ardizzoni A (2001) Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines Lung Cancer 33, 27–39 24 Perkins ND (2004) NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14, 64–69 25 Siwak DR, Shishodia S, Aggarwal BB & Kurzrock R (2005) Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf ⁄ mitogen-activated ⁄ extracellular signal-regulated protein kinase pathway and the Akt pathway Cancer 104, 879–890 26 Takada Y, Bhardwaj A, Potdar P & Aggarwal BB (2004) Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Oncogene 23, 9247–9258 27 Aggarwal BB, Kumar A & Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res 23, 363–398 28 Korcok J, Du Raimundo LNX, Sims SM & Dixon SJ (2005) P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts J Biol Chem 280, 16909–16915 29 Schafer R, Sedehizade F, Welte T & Reiser G (2003) ă ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells Am J Physiol Lung Cell Mol Physiol 285, L376–L385 30 Afework M & Burnstock G (2005) Changes in P2Y2 receptor localization on adrenaline- and noradrenalinecontaining chromaffin cells in the rat adrenal gland during development and aging Int J Dev Neurosci 23, 567–573 31 Cheung KK, Ryten M & Burnstock G (2003) Abundant and dynamic expression of G protein-coupled P2Y receptors in mammalian development Dev Dyn 228, 254–266 32 Wang L, Jacobsen SE, Bengtsson A & Erlinge D (2004) P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells BMC Immunol 5, 16 33 Marteau F, Communi D, Boeynaems JM & Suarez Gonzalez N (2004) Involvement of multiple P2Y receptors and signaling pathways in the action of adenine FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS R Schafer et al ă 34 35 36 37 38 39 40 41 42 43 44 45 nucleotides diphosphates on human monocyte-derived dendritic cells J Leukoc Biol 76, 796–803 Lenz G, Gottfried C, Luo Z, Avruch J, Rodnight R, Nie WJ, Kang Y & Neary JT (2000) P2Y purinoceptor subtypes recruit different mek activators in astrocytes Br J Pharmacol 129, 927–936 Budagian V, Bulanova E, Brovko L, Orinska Z, Fayad R, Paus R & Bulfone-Paus S (2003) Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B J Biol Chem 278, 1549–1560 Aga M, Johnson CJ, Hart AP, Guadarrama AG, Suresh M, Svaren J, Bertics PJ & Darien BJ (2002) Modulation of monocyte signaling and pore formation in response to agonists of the nucleotide receptor P2X (7) J Leukocyte Biol 72, 222–232 Young KM, Bartlett PF & Coulson EJ (2006) Neural progenitor number is regulated by nuclear factor-kappaB p65 and p50 subunit-dependent proliferation rather than cell survival J Neurosci Res 83, 39–49 Mathas S, Johrens K, Joos S, Lietz A, Hummel F, Janz M, Jundt F, Anagnostopoulos I, Bommert K, Lichter P et al (2005) Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas Blood 106, 4287–4293 Pouyssegur J & Lenormand P (2003) Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling Eur J Biochem 270, 3291–3299 Roberts EC, Shapiro PS, Nahreini TS, Pages G, Pouyssegur J & Ahn NG (2002) Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis Mol Cell Biol 22, 7226–7241 Zarubin T & Han J (2005) Activation and signaling of the p38 MAP kinase pathway Cell Res 15, 11–18 Wilkinson MG & Millar JB (2000) Control of the eukaryotic cell cycle by MAP kinase signaling pathways FASEB J 14, 2147–2157 Pearce AK & Humphrey TC (2001) Integrating stressresponse and cell-cycle checkpoint pathways Trends Cell Biol 11, 426–433 MacCorkle RA & Tan TH (2005) Mitogen-activated protein kinases in cell-cycle control Cell Biochem Biophys 43, 451–461 Berasi SP, Xiu M, Yee AS & Paulson KE (2004) HBP1 repression of the p47phox gene: cell cycle regulation via the NADPH oxidase Mol Cell Biol 24, 3011–3024 ATP and ADP inhibit lung cell proliferation 46 Spaziani A, Alisi A, Sanna D & Balsano C (2006) Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1 J Biol Chem 281, 10983–10989 47 Pedraza-Alva G, Koulnis M, Charland C, Thornton T, Clements JL, Schlissel MS & Rincon M (2006) Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2 ⁄ M cell cycle checkpoint EMBO J 25, 763–773 48 Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS & Pieper RO (2003) The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents Mol Cell Biol 23, 8306–8315 49 Fan L, Du Yang XJ, Marshall M, Blanchard K & Ye X (2005) A novel role of p38alpha MAPK in mitotic progression independent of its kinase activity Cell Cycle 4, 1616–1624 50 Boutros R, Dozier C & Ducommun B (2006) The when and wheres of CDC25 phosphatases Curr Opin Cell Biol 18, 185–191 51 Mikhailov A, Shinohara M & Rieder CL (2004) Topoisomerase II and histone deacetylase inhibitors delay the G2 ⁄ M transition by triggering the p38 MAPK checkpoint pathway J Cell Biol 166, 517–526 52 Takenaka K, Moriguchi T & Nishida E (1998) Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest Science 280, 599–602 53 Beinke S & Ley SC (2004) Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology Biochem J 382, 393–409 54 Ye RD (2001) Regulation of nuclear factor kappaB activation by G-protein-coupled receptors J Leukocyte Biol 70, 839–848 55 Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM & Palumbo G (2006) Low doses of cisplatin or gemcitabine plus photofrin ⁄ photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299) Mol Cancer Ther 5, 776–785 56 Murphy LO, Smith S, Chen RH, Fingar DC & Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products Nat Cell Biol 4, 556– 564 57 Takeda DY & Dutta A (2005) DNA replication and progression through S phase Oncogene 24, 2827–2843 FEBS Journal 273 (2006) 3756–3767 ª 2006 The Authors Journal compilation ª 2006 FEBS 3767 ... Attenuation of LXF-289 cell proliferation by ATP is mediated by the activation of the MEK ⁄ ERK1 ⁄ 2, PI3K and p38 MAPK pathways Activation and translocation of the transcription factors NF -jB1 (p50) and. .. Table Inhibition of proliferation of LXF-289 lung tumor cells Effects of signaling pathway inhibitors on ATP-inhibited proliferation (A) and of basal proliferation (B) of LXF-289 lung tumor cells... and ADP in the inhibition of LXF-289 cell proliferation Cell cycle analysis revealed that inhibition of proliferation of LXF-289 cells by ATP and ADP was mediated by retardation of cell cycle

Ngày đăng: 07/03/2014, 12:20

Từ khóa liên quan

Tài liệu cùng người dùng

  • Đang cập nhật ...

Tài liệu liên quan